Business Context and Reporting Period
This Form 8-K is a current report filed by Catalyst Biosciences, Inc. (not Gyre Therapeutics, Inc.) on June 10, 2021, regarding events occurring on June 9, 2021. The filing details the results of the Company's Annual Meeting of Stockholders held via live audio webcast.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for any financial metrics.
Material Changes and Corporate Actions
- Equity Plan Amendment: Stockholders approved an amendment to the 2018 Omnibus Incentive Plan, increasing the number of shares reserved for issuance by 2,500,000 to a total of 5,300,000 shares.
- Board Elections: Stockholders elected two Class III directors, Errol B. De Souza, Ph.D., and Sharon Tetlow, to three-year terms.
- Executive Compensation: Stockholders approved the compensation of Named Executive Officers on a non-binding, advisory basis.
- Auditor Ratification: Stockholders ratified the appointment of EisnerAmper LLP as the independent registered accounting firm for the fiscal year ending December 31, 2021.
Voting Results and Participation
Holders of 25,242,893 shares, representing approximately 80.52% of total outstanding shares eligible to be voted, were present virtually or by proxy. The voting outcomes were as follows:
| Proposal | Votes For | Votes Against/Withheld | Abstentions |
|---|---|---|---|
| Election of Directors (Errol B. De Souza) | 15,351,802 | 2,756,965 (Withheld) | N/A |
| Election of Directors (Sharon Tetlow) | 16,219,366 | 1,889,401 (Withheld) | N/A |
| Approval of 2018 Plan Amendment | 13,636,195 | 4,462,183 | 10,389 |
| Executive Compensation (Say-on-Pay) | 15,954,188 | 2,118,540 | 36,039 |
| Ratification of Auditor | 24,162,144 | 1,040,164 | 40,585 |
Outlook, Risks, and Contingencies
The filing contains no management commentary regarding future outlook, risks, contingencies, or unusual items. It strictly reports on the administrative outcomes of the Annual Meeting.
Investor Verification Checklist
- Verify the exact number of shares reserved under the amended 2018 Omnibus Incentive Plan (5,300,000 total).
- Confirm the tenure of the newly elected directors (three-year terms).
- Review the definitive proxy statement filed on April 27, 2021, for detailed terms of the incentive plan.
- Note the significant number of broker non-votes (7,134,126) across all proposals, indicating shares held by brokers that were not voted on discretionary matters.